# A Phase Ⅲ Clinical Study of SNA02-48 Injection

> **NCT07633119** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Tetanus

## Interventions

- **DRUG:** SNA02-48
- **DRUG:** Human tetanus immunoglobulin (HTIG)

## Key facts

- **NCT ID:** NCT07633119
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-28
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633119, "A Phase Ⅲ Clinical Study of SNA02-48 Injection". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*